Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data

Biohaven Ltd. (NYSE:BHVN) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds.

On March 11, Ken Cacciatore from TD Cowen increased the price target on Biohaven Ltd. (NYSE:BHVN) from $15 to $30. The analyst maintained a Buy rating on the stock, which yields an adjusted upside potential of more than 258% at the prevailing level.

Copyright: jezper / 123RF Stock Photo

Since significant azetukalner data has now clearly validated the Kv7 MoA in focal epilepsy, the analyst has revised his model. He is also encouraged by the prospect of being able to promote the company based on its unique CNS AE profile, which is a positive factor leading up to the topline opakalim data expected mid-year.

On March 10, Goldman Sachs maintained a Buy rating on Biohaven Ltd. (NYSE:BHVN). The firm increased its price target from $24 to $27. Goldman Sachs cited positive read-through from strong Phase 3 data reported by Xenon Pharmaceuticals, noting the results support confidence in the broader Kv7 class.

The firm added that the data, along with potential premium pricing versus existing therapies, strengthens the outlook for Biohaven’s pipeline and long-term growth potential.

Biohaven Ltd. (NYSE:BHVN) focuses on developing and commercializing medicines in the fields of immunology, neuroscience, and oncology. Its clinical stage products include Opakalim, BHV-1300, BHV-1400, BHV-1600, and more. The company also has a strong preclinical product pipeline that includes BHV-1310, BHV- 1320, BHV-1450, and more.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.